drugset / Trial / NCT01830361
Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML
NaSingle-groupOpen-labelTreatment
Summary
To assess the efficacy of tyrosine-kinase inhibitor midostaurin in c-KIT or FLT3-ITD mutated t(8;21) AML. To assess the efficacy of midostaurin depending on the type of c-KIT mutation
Timeline
- Start
- 2013-03-13
- Primary completion
- 2019-10-30
- Completion
- 2019-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Midostaurin | Small molecule | 50 mg | — |